Anika Therapeutics, Inc.
$193.30M- Market cap
- $274.62M
- Debt
- +-$149.00K
- Cash
- −$81.17M
Capital structure 100% equity / -0% debt · EV / Revenue 1.71x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: ANIK stock price near parity vs SLB $20.52 current versus $20.41 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at SLB's multiple
Implied fair value · at ANIK's multiple
Snapshot Sep 8, 11:10 AM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ANIK FY 2025 (ended Dec 31, 2025) · SLB FY 2025 (ended Dec 31, 2025).
Trendline
Seven fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 100% equity / -0% debt · EV / Revenue 1.71x
Capital structure 90% equity / 10% debt · EV / Revenue 2.58x · EV / EBITDA 13.37x
SLB carries the larger enterprise value at $91.97B against $193.30M; ANIK trades on the lower EV / Revenue multiple (1.71x vs 2.58x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Anika Therapeutics, Inc. · implied price per share
At least 3 of the last 5 annual free-cash-flow observations must be positive.
SLB LIMITED/NV · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
-0.00x
0.37x
Net debt / EBITDA
Leverage against operating earnings
34.65x
0.80x
Cash and equivalents
Liquid reserves on the balance sheet
$81.17M
$4.21B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
ZIMMER BIOMET HOLDINGS, INC.
ANIK vs ZBH
STRYKER CORP
ANIK vs SYK
BECTON DICKINSON & CO
ANIK vs BDX
INTEGRA LIFESCIENCES HOLDINGS CORP
ANIK vs IART
HALLIBURTON CO
ANIK vs HAL
TechnipFMC plc
ANIK vs FTI
Helmerich & Payne, Inc.
ANIK vs HP
VALERO ENERGY CORP/TX
ANIK vs VLO
ONEOK INC /NEW/
ANIK vs OKE
EXXON MOBIL CORP
ANIK vs XOM
-$149.00K
$9.74B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.